✉ Email this page to a colleague
« Back to Dashboard
Setipiprant is an investigational drug.
There have been 4 clinical trials for Setipiprant. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Rhinitis, Allergic, Seasonal. The leading clinical trial sponsors are Actelion, Idorsia Pharmaceuticals Ltd., and Allergan.
Recent Clinical Trials for Setipiprant
|A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males||Allergan||Phase 2|
|Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis||Actelion||Phase 3|
|Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis||Idorsia Pharmaceuticals Ltd.||Phase 3|